ATE368116T1 - Schutzantigen des epstein-barr-virus - Google Patents

Schutzantigen des epstein-barr-virus

Info

Publication number
ATE368116T1
ATE368116T1 AT00954003T AT00954003T ATE368116T1 AT E368116 T1 ATE368116 T1 AT E368116T1 AT 00954003 T AT00954003 T AT 00954003T AT 00954003 T AT00954003 T AT 00954003T AT E368116 T1 ATE368116 T1 AT E368116T1
Authority
AT
Austria
Prior art keywords
ebna
barr virus
epstein
protective antigens
vaccine
Prior art date
Application number
AT00954003T
Other languages
English (en)
Inventor
Ralph Steinman
Christian Muenz
Original Assignee
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rockefeller filed Critical Univ Rockefeller
Application granted granted Critical
Publication of ATE368116T1 publication Critical patent/ATE368116T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00954003T 1999-08-13 2000-08-10 Schutzantigen des epstein-barr-virus ATE368116T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14897199P 1999-08-13 1999-08-13

Publications (1)

Publication Number Publication Date
ATE368116T1 true ATE368116T1 (de) 2007-08-15

Family

ID=22528253

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00954003T ATE368116T1 (de) 1999-08-13 2000-08-10 Schutzantigen des epstein-barr-virus

Country Status (7)

Country Link
EP (1) EP1200594B1 (de)
JP (1) JP2004500335A (de)
AT (1) ATE368116T1 (de)
AU (1) AU775760B2 (de)
CA (1) CA2380991A1 (de)
DE (1) DE60035695T2 (de)
WO (1) WO2001012215A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3020413A1 (de) * 2002-01-30 2016-05-18 The Brigham and Women's Hospital, Inc. Zusammensetzungen und Verfahren im Zusammenhang mit TIM-3, A TH1-spezifischem Zelloberflächenmolekül
US7422751B2 (en) * 2002-06-14 2008-09-09 Mayo Foundation For Medical Education And Research Epstein-barr-virus-specific immunization
CN1902227A (zh) * 2003-10-03 2007-01-24 布赖汉姆妇女医院 Tim－3配体及其方法
JP4956427B2 (ja) * 2004-07-21 2012-06-20 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド レンチウイルスベクターおよびその使用
US20070196389A1 (en) * 2005-11-18 2007-08-23 The Ohio State University Research Foundation Viral gene products and methods for vaccination to prevent viral associated diseases
JP2015516376A (ja) 2012-03-19 2015-06-11 ドイチェス クレブスフォルシュンクスツェントルム Ｔ細胞エピトープを含む、ｂ細胞受容体複合体結合タンパク質

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0770090A1 (de) * 1994-07-13 1997-05-02 Cornell Research Foundation, Inc. Protein des epstein-barr virus kernantigen 1 und seine expression und anreicherung
CA2180193A1 (en) * 1995-06-28 1996-12-29 Edward Baral Enhancing host immunity against viral infections
WO1997024447A1 (en) * 1996-01-02 1997-07-10 Chiron Corporation Immunostimulation mediated by gene-modified dendritic cells

Also Published As

Publication number Publication date
WO2001012215A3 (en) 2001-08-23
EP1200594A2 (de) 2002-05-02
DE60035695T2 (de) 2008-04-10
AU6636200A (en) 2001-03-13
DE60035695D1 (de) 2007-09-06
EP1200594B1 (de) 2007-07-25
JP2004500335A (ja) 2004-01-08
CA2380991A1 (en) 2001-02-22
AU775760B2 (en) 2004-08-12
WO2001012215A2 (en) 2001-02-22

Similar Documents

Publication Publication Date Title
Long et al. CD4+ T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines
Khanna et al. Vaccine strategies against Epstein‐Barr virus‐associated diseases: lessons from studies on cytotoxic T‐cell‐mediated immune regulation
Cohen Vaccine development for Epstein-Barr virus
Lee et al. CD8 T cell recognition of endogenously expressed Epstein-Barr virus nuclear antigen 1
Rowe et al. Burkitt's lymphoma: the Rosetta Stone deciphering Epstein-Barr virus biology
Leen et al. Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4+ T-helper 1 responses
CN100526331C (zh) 来自ebv的ctl表位
CY1106785T1 (el) Ιικα σωματιδια τα οποια απελευθερωνονται μετα απο μολυνση απο ανθρωπινο κυτταρομεγαλοϊο και η χρηση τους ως εμβολιο
Thorley-Lawson et al. Generation of specific cytotoxic T cells with a fragment of the Epstein-Barr virus-encoded p63/latent membrane protein.
HUP0202804A2 (hu) Új készítmény
HUP0202826A2 (hu) Új készítmény
Bourgault et al. Limiting-dilution analysis of the HLA restriction of anti-Epstein-Barr virus-specific cytolytic T lymphocytes.
Hislop et al. T-cell responses to EBV
ES2009350A6 (es) Procedimiento para la preparacion de vectores de expresion que codifican una nueva proteina.
MY135965A (en) Vaccine against hepatitis b and herpes simplex virus
EE9800105A (et) Dendriitrakke stimuleeriv faktor
TR200200838T2 (tr) İmmunolojik olarak önemli herpes simpleks virüs antijenleri.
NZ322910A (en) Tumour vaccine containing tumour cells, some with MHC-I-haplotype on cell surface to trigger immune response, and preparation of vaccine thereof
DK1523582T3 (da) Hurtig, effektiv rensning af HSV-specifikke T-lymfocytter samt HSV-antigener identificeret derved
ATE368116T1 (de) Schutzantigen des epstein-barr-virus
UA84667C2 (ru) Вакцина, направленная против инфекции, вызванной вирусом герпеса болезни марека
TR200102034T2 (tr) Anti kanser aşılaması için antikorların kullanılması
Khanna et al. Immunotherapeutic strategies for EBV-associated malignancies
Lockey et al. Epstein-Barr virus vaccine development: a lytic and latent protein cocktail
Wiesner et al. Selection of CMV‐specific CD8+ and CD4+ T cells by mini‐EBV‐transformed B cell lines

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties